In HER2+ BC cells with PIK3CA mutations, the attenuation of lapatinib’s effects by p4EBP1 is even more pronounced [24], suggesting that p4EBP1 has potential as a biomarker in terms of the efficacy of anti-HER2 therapies. Here, ERBB2 is linked to breast cancer.